These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 2314636

  • 1. Thioridazine chronic administration: a behavioural and autoradiographic study.
    Calzà L, Giardino L, Piazza PV, Amato G.
    Neurosci Lett; 1990 Feb 05; 109(1-2):206-11. PubMed ID: 2314636
    [Abstract] [Full Text] [Related]

  • 2. Chronic thioridazine treatment differently affects DA receptors in striatum and in mesolimbo-cortical systems.
    Piazza PV, Calzà L, Giardino L, Amato G.
    Pharmacol Biochem Behav; 1990 Apr 05; 35(4):937-42. PubMed ID: 2345767
    [Abstract] [Full Text] [Related]

  • 3. Behavioral and neurochemical modifications induced by apomorphine treatment.
    Piervincenzo P, Luciana G, Laura C, Giuseppe A.
    Neurosci Lett; 1989 May 22; 100(1-3):265-70. PubMed ID: 2761776
    [Abstract] [Full Text] [Related]

  • 4. Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.
    Köhler C, Haglund L, Ogren SO, Angeby T.
    J Neural Transm; 1981 May 22; 52(3):163-73. PubMed ID: 7198139
    [Abstract] [Full Text] [Related]

  • 5. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF, Thal L, Gardner EL.
    Psychopharmacology (Berl); 1982 May 22; 76(2):182-7. PubMed ID: 6805029
    [Abstract] [Full Text] [Related]

  • 6. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
    Globus M, Bannet J, Lerer B, Belmaker RH.
    Psychopharmacology (Berl); 1982 May 22; 78(1):81-4. PubMed ID: 6815701
    [Abstract] [Full Text] [Related]

  • 7. The effects of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity.
    Dewey KJ, Fibiger HC.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 May 22; 322(4):261-70. PubMed ID: 6683359
    [Abstract] [Full Text] [Related]

  • 8. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J, Devanand DP, Carey RJ.
    Biol Psychiatry; 1982 Nov 22; 17(11):1289-301. PubMed ID: 6891268
    [Abstract] [Full Text] [Related]

  • 9. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A, Theodorou A, Jenner P, Marsden CD.
    Eur J Pharmacol; 1980 May 02; 63(2-3):145-57. PubMed ID: 6103814
    [Abstract] [Full Text] [Related]

  • 10. Effects of acute thioridazine, metoclopramide and SCH 23390 on the basal activity of A9 and A10 dopamine cells.
    Hand TH, Kasser RJ, Wang RY.
    Eur J Pharmacol; 1987 Jun 04; 137(2-3):251-5. PubMed ID: 2886354
    [Abstract] [Full Text] [Related]

  • 11. Effects of chronic haloperidol, thioridazine and zotepine treatment on apomorphine elicited stereotypic behavior and 3H-spiroperidol binding sites in the striatum of the rat.
    Lai HC, Carino MA, Horita A.
    Proc West Pharmacol Soc; 1981 Jun 04; 24():5-6. PubMed ID: 6114496
    [No Abstract] [Full Text] [Related]

  • 12. Enhanced stereotypic behavior by chronic treatment with bromocriptine accompanies increase of D-1 receptor binding.
    Le WD, Zhou XD, Jin GZ.
    Life Sci; 1988 Jun 04; 42(19):1841-5. PubMed ID: 2966885
    [Abstract] [Full Text] [Related]

  • 13. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.
    Niedzwiecki DM, Cubeddu LX, Mailman RB.
    J Pharmacol Exp Ther; 1989 Jul 04; 250(1):117-25. PubMed ID: 2746491
    [Abstract] [Full Text] [Related]

  • 14. Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.
    Carvey PM, Kao LC, Zhang TJ, Amdur RL, Lin DH, Singh R, Klawans HL.
    Pharmacol Biochem Behav; 1990 Feb 04; 35(2):291-300. PubMed ID: 2320636
    [Abstract] [Full Text] [Related]

  • 15. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O, Roncada P, Dall'Olio R, Montanaro N.
    Brain Res; 1988 Jul 12; 455(2):390-3. PubMed ID: 2969768
    [Abstract] [Full Text] [Related]

  • 16. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD.
    Biochem Pharmacol; 1983 Oct 01; 32(19):2921-7. PubMed ID: 6138043
    [Abstract] [Full Text] [Related]

  • 17. Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat.
    Lai H, Carino MA, Horita A.
    Psychopharmacology (Berl); 1981 Oct 01; 75(4):388-90. PubMed ID: 6122233
    [Abstract] [Full Text] [Related]

  • 18. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat.
    Carter CJ, Pycock CJ.
    Brain Res; 1980 Jun 16; 192(1):163-76. PubMed ID: 7189685
    [Abstract] [Full Text] [Related]

  • 19. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M.
    J Neural Transm Suppl; 1986 Jun 16; 22():33-45. PubMed ID: 2946813
    [Abstract] [Full Text] [Related]

  • 20. Relation between brain catecholamine receptors and dopaminergic stereotypy in rat strains.
    Helmeste DM, Seeman P, Coscina DV.
    Eur J Pharmacol; 1981 Feb 19; 69(4):465-70. PubMed ID: 6265228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.